Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €32.49 EUR
Change Today +0.92 / 2.91%
Volume 0.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:40 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Open
€31.85
Previous Close
€31.58
Day High
€32.60
Day Low
€31.58
52 Week High
08/17/15 - €33.36
52 Week Low
01/14/15 - €9.62
Market Cap
1.3B
Average Volume 10 Days
135.1
EPS TTM
--
Shares Outstanding
41.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (AB3A)

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

204 Employees
Last Reported Date: 02/26/15
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Interim Chief Executive Officer, Chief Medica...
Total Annual Compensation: $399.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $443.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $393.4K
Senior Vice President of Technical Operations
Total Annual Compensation: $335.9K
Compensation as of Fiscal Year 2014.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Therapeutics, Inc. Announces FDA Filing of Eteplirsen NDA for Potential Treatment of Duchenne Muscular Dystrophy for Patients Amenable to Exon 51 Skipping

Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has filed the New Drug Application (NDA) for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Approximately 13% of people with Duchenne muscular dystrophy are estimated to have a mutation addressable by Eteplirsen/exon 51 skipping. The FDA has completed its filing review and has determined that application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) action date for a decision on the application is February 26, 2015. The FDA has granted eteplirsen Priority Review status, which is designated to drugs that offer benefit over existing therapies, or provide a treatment where no adequate therapy exists.

Sarepta Therapeutics, Inc. Announces Formation of Strategic & Scientific Advisory Board

Sarepta Therapeutics, Inc. announced the formation of a Strategic & Scientific Advisory Board (SSAB) with three key appointments: Louis Kunkel, PhD, Beverly Davidson, PhD, and Jeffrey Chamberlain, PhD. The board will work closely with the company’s management team to advance the company’s platform technology in Duchenne muscular dystrophy (DMD), identify multiple new applications for the company’s proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the company’s pipeline. The initial appointments to the company’s strategic & scientific advisory board include: Louis M. Kunkel, PhD, Past Chief of the Division of Genetics and currently a member of the Division of Genetics and Genomics, Boston Children’s Hospital. Dr. Kunkel is responsible for the identification of the gene and encoded protein, dystrophin. He has received numerous awards and honors for scientific leadership and achievement and currently serves as the committee chair for the Muscular Dystrophy Association (MDA), a committee he has been a member of for over 15 years; Beverly Davidson, PhD, Director of the Raymond G Perelman Center for Cellular and Molecular Therapeutics and Arthur V. Meigs Chair in Pediatrics, Children’s Hospital of Philadelphia; Professor in the Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. Dr. Davidson’s research focuses on the pathogenesis and therapy of hereditary neurogenetic diseases and the role of noncoding RNAs in neural development. She is an internationally known expert in the study of inherited neurological diseases and the development of molecular therapies. Dr. Davidson has been named a fellow by the American Association for the Advancement of Science, received the NIH Mathilde Solowey Award, was elected to the Advisory Council for the American Society of Gene and Cell Therapy and NINDS council, and was past chair of the Medical Sciences Section for the American Association for the Advancement of Science; Jeffrey Chamberlain, PhD, Professor in the Departments of Neurology, Medicine, and Biochemistry; McCaw Endowed Chair in Muscular Dystrophy at the University of Washington; Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center of Seattle. Dr. Chamberlain’s research is primarily focused on two major goals: to develop a better understanding of the molecular basis of the pathophysiology of muscle disorders, and to develop gene and cell therapies that will correct and treat the muscular dystrophies. Dr. Chamberlain is a close collaborator with a number of prominent institutions, including Children’s Hospital of Seattle, Fred Hutchinson Research Center, University of Rochester, and Harborview Medical Center. Dr. Chamberlain also serves on the advisory boards for CureDuchenne, Akashi Therapeutics, and Solid Ventures.

Sarepta Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Sarepta Therapeutics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, the company reported operating loss was $42,107,000 compared with $30,271,000 for the same period in the last year. Net loss was $41,851,000 compared with $33,874,000 for the same period in the last year. Net loss per basic and diluted share was $1.01 compared with $0.85 for the same period in the last year. Non-GAAP net loss was $35,921,000 compared with $24,501,000 for the same period in the last year. Non-GAAP net loss per basic and diluted share was $0.87 compared with $0.61 for the same period in the last year. The incremental loss of $11.4 million was primarily the result of increased operating expenses as well as a decrease in revenue from the company's government contracts. The increase in net loss was primarily due to a decrease of $2.6 million from government contract revenue and increases of $8.5 million from research and development expenses and $0.7 million from general and administrative expenses. For the six months, the company reported operating loss was $103,969,000 compared with $55,392,000 for the same period in the last year. Net loss was $103,410,000 compared with $62,147,000 for the same period in the last year. Net loss per basic and diluted share was $2.50 compared with $1.60 for the same period in the last year. Non-GAAP net loss was $83,324,000 compared with $45,172,000 for the same period in the last year. Non-GAAP net loss per basic and diluted share was $2.02 compared with $1.16 for the same period in the last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €32.49 EUR +0.92

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $7.36 USD +0.09
Dicerna Pharmaceuticals Inc $11.13 USD +0.89
Galena Biopharma Inc $1.50 USD +0.01
Regulus Therapeutics Inc $8.27 USD +0.79
Silence Therapeutics PLC 258.50 GBp -1.50
View Industry Companies
 

Industry Analysis

AB3A

Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,379.7x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,216.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.